Semaglutide (Ozempic®)

Assessment Status Rapid Review Complete
Drug Semaglutide
Brand Ozempic®
Indication For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise/as monotherapy when metformin is considered inappropriate due to intolerance or contraindications/in addition to other medicinal products for the treatment of diabetes
Assessment Process
Rapid review commissioned 12/03/2018
Rapid review completed 10/04/2018
Rapid review outcome A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.

The HSE has approved reimbursement September 2018.